Insulin soluble [human genetic engineering] (Insulinum solubile [humanum biosyntheticum])

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Insulins

Included in the formulation
  • Actrapid® HM
    solution for injections 
    Novo Nordisk A / S     Denmark
  • Actrapid® HM Penfill®
    solution for injections 
    Novo Nordisk A / S     Denmark
  • Biosulin® R
    solution for injections 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Vozulim-R
    solution for injections 
    Vokhard Ltd     India
  • Gensulin R
    solution for injections 
    BIOTEK MFPDK, CJSC     Russia
  • Insuman Rapid GT
    solution for injections 
    Sanofi-Aventis Deutschland GmbH     Germany
  • Insuran R
    solution for injections 
    Institute of Bioorganic Chemistry, Academy of Sciences MM Shemyakin and Yu.A. Ovchinnikov Institute of RAS     Russia
  • Monoinsulin CR
    solution for injections 
    VIAL, LLC     Russia
  • Rinsulin® R
    solution for injections 
    GEROPHARM-BIO, JSC     Russia
  • Rinsulin® R
    solution for injections 
    GEROPHARM-BIO, JSC     Russia
  • Rosinsulin R
    solution for injections 
    MEDSINTEZ FACTORY, LTD.     Russia
  • Humodar® R 100 Rivers
    solution for injections 
    Indar, Inc. for the production of insulin     Ukraine
  • Humulin Regular
    solution for injections 
    Eli Lilly East SA     Switzerland
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    ONLS

    АТХ:

    A.10.A.B.01   Insulin (human)

    Pharmacodynamics:

    It interacts with insulin receptors of fat and muscle tissues, increasing intracellular transport of glucose, simultaneously inhibits the formation of glucose in the liver.Due to the assimilation of glucose by cells, a reduction in its level in the blood plasma is achieved.

    With subcutaneous injection, the onset of action occurs after 30 minutes, the maximum effect occurs between 1 and 3 hours. The duration of the action is 8 hours.

    Pharmacokinetics:

    After subcutaneous administration, the maximum concentration in the blood plasma is reached after 30 minutes. The connection with plasma proteins is 0-9%.

    The residence time in the systemic circulation is 161 minutes. Does not penetrate the blood-brain and placental barrier, does not enter the breast milk. Metabolism in the liver and kidneys is destroyed by insulinase.

    The half-life is 20-30 minutes. Elimination by the kidneys.

    Indications:

    It is used for the purpose of hormone replacement therapy in diabetes mellitus I type.

    ICD-10

    IV.E10-E14.E11   Non-insulin-dependent diabetes mellitus

    IV.E10-E14.E10   Insulin-dependent diabetes mellitus

    Contraindications:

    Hypoglycemia, individual intolerance.

    Carefully:

    Hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used during pregnancy and lactation.

    Dosing and Administration:

    Subcutaneously, 30 minutes before a meal. The daily dose is calculated from 0.5 to 1 IU / kg body weight. With an increase in the daily dose of more than 0.6 IU / kg, it is recommended to administer a dose for two or more injections to different parts of the body.

    Side effects:

    Central and peripheral nervous system: rapid stabilization of blood glucose levels at the beginning of therapy can lead to acute pain neuropathy, which is transient.

    Dermatological reactions: lipodystrophy at the injection site.

    Sense organs: refractive disorders, decreased visual acuity - is also associated with the rapid stabilization of blood glucose at the beginning of therapy, is transient.

    Allergic reactions.

    Overdose:

    Hypoglycemia.

    With the development of hypoglycemic coma intravenously struino inject 20-40 (up to 100 ml) 40% dextrose solution until the patient does not come out of the coma.

    Interaction:

    Hypoglycemic action increases α- and β-adrenoblockers, salicylates, disopyramide, tetracyclines, monoamine oxidase inhibitors, ACE inhibitors, alcohol, sulfonamides, anabolic steroids.

    Weaken the action of insulin β-adrenomimetics, glucocorticoids, sympathomimetics, thiazide diuretics.

    Special instructions:

    Intravenous administration of the drug is carried out only in specialized departments of endocrinology.

    When using insulin aspartame in insulin pumps (pumps) for subcutaneous administration, mixing of the drug with other solutions is prohibited.

    Intensive physical activity, as well as concomitant infectious and inflammatory processes require an additional amount of insulin.

    At the beginning It is not recommended to drive vehicles and work with moving mechanisms due to visual impairment. With constant intake of the drug should be careful in connection with the possible development of hypoglycemia.

    Instructions
    Up